By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Janssen, L.P. 

1125 Trenton-Harbourton Road

Titusville  New Jersey  08560-0200  U.S.A.
Phone: 609-730-2000 Fax: 609-730-2323





Company News
Janssen, L.P.'s RISPERDAL(R) CONSTA(R) (Risperidone) Long-Acting Treatment Delayed the Time to Relapse in Patients with Bipolar I Disorder 5/20/2009 8:52:04 AM
Janssen, L.P. New Data Demonstrate RISPERDAL(R) CONSTA(R) (Risperidone) Long-Acting Treatment May Improve Health Outcomes and Reduce Hospitalizations in Patients with Schizophrenia 5/19/2009 11:05:33 AM
FDA Grants Approval for Use of Janssen, L.P.'s RISPERDAL(R) CONSTA(R) as Both a Monotherapy and Adjunctive Therapy in the Maintenance Treatment of Bipolar I Disorder 5/18/2009 7:22:46 AM
Janssen, L.P. Phase 3 Data Demonstrate Efficacy and Tolerability of Paliperidone Palmitate, an Investigational Long-Acting Therapy for the Treatment of Schizophrenia 12/10/2008 7:32:58 AM
Janssen, L.P. Announces Launch of Authorized Generic for RISPERDAL(R) 7/1/2008 10:27:11 AM
Janssen, L.P. Release: Study Suggests Risperidone Long-Acting Injection Combined with Standard Treatment Helped Delay Time to Relapse in Patients with Bipolar Disorder 2/4/2008 8:10:40 AM
Janssen, L.P. INVEGA(TM) Significantly Reduced Symptoms of Schizophrenia Compared to SEROQUEL(R) in Acutely Ill, Hospitalized Patients 10/15/2007 9:25:54 AM
Janssen, L.P. and Johnson and Johnson Pharmaceutical R&D (NJ) Release: FDA Approves RISPERDAL(R) to Treat Adolescents with Schizophrenia and Children and Adolescents with Bipolar Mania 8/22/2007 11:04:34 AM
Janssen, L.P. Blood Levels of Paliperidone Extended-Release Tablets are Not Increased by Common Antidepressant 5/23/2007 11:26:08 AM
FDA Approves New Dose of Janssen, L.P. and Alkermes (ALKS)'s RISPERDAL(R) CONSTA(R) for Schizophrenia Treatment 4/13/2007 9:41:19 AM